RegionInternational. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  GHK-Cu Peptide (Copper Tripeptide-1)
Research reference — not for sale

GHK-Cu Peptide (Copper Tripeptide-1)

B
lead outcome
Topical: appearance of photoaged skin (fine…
grades vary by outcome ↓
Peptide
also called — GHK · GHK peptide · GHK-Cu peptide · GHK Cu · copper peptide · copper tripeptide
skin appearance (cosmetic)antioxidant(research context:) tissue repairangiogenesishair

Dual-form compound. The topical form (INCI Copper Tripeptide-1) is a lawful cosmetic ingredient — this is the sellable serum. The injectable / systemic form is a research compound, not approved. Reference science below is neutral; the sellable product uses cosmetic (appearance/feel) claims only — see the cosmetic_claims block above.

In brief

GHK-Cu is a naturally occurring copper-binding tripeptide. As a topical cosmetic ingredient it has several small human studies showing improved appearance of photoaged skin (fine lines, firmness, density). As an injectable / systemic "research" compound it is studied mainly in vitro and in animals, with little human data and no approval. A well-documented limitation: GHK-Cu barely penetrates intact skin, so topical results depend heavily on formulation and delivery.

Legal standing, by region
International
See note

Topical (INCI Copper Tripeptide-1) — a lawful cosmetic ingredient in the EU (Regulation (EC) 1223/2009) and widely used globally; this is the form sold. Claims are constrained by cosmetic regulation — see the cosmetic_claims block. Injectable / systemic — Not approved anywhere as a medicine. EU: not eligible for magistral / officinal compounding (no Ph. Eur. monograph exists). US: on 15 April 2026 the FDA removed injectable GHK-Cu from the Category 2 bulks list (previously restricting 503A compounding since 2023–2024) but did NOT add it to Category 1 — creating an interim regulatory posture. A PCAC (Pharmacy Compounding Advisory Committee) review of both injectable and non-injectable GHK-Cu is scheduled before end-February 2027; some 503A compounding pharmacies have resumed preparation on the basis of the Category 2 removal, others await affirmative Category 1 authorization. The topical / non- injectable route sits on Category 1 pending the same PCAC review. Recheck the early-2027 PCAC outcome before any US injectable references are updated.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: appearance of photoaged skin (fine lines, firmness, density)
Small samples; effect generally smaller than prescription retinoids; highly formulation-dependent
Small human RCTs — Leyden 2002 (n=71), eye-cream (n=41), Badenhorst 2016 (nano-carrier vs Matrixyl 3000) · Measurable improvement
B
Collagen/elastin synthesis & balanced MMP/TIMP remodeling
In vitro; in-vivo relevance limited by skin penetration
In-vitro fibroblast studies (Maquart 1988; Pickart) · Stimulates synthesis; orderly turnover
B
Skin penetration of intact-skin serums
Key limitation; most benefit shown with enhanced delivery or penetration-optimised formulas
Permeation study (Li 2015) · Near-zero through intact stratum corneum
Post-procedure wound healing (e.g., after laser resurfacing)
Medicinal context — not a cosmetic-product claim
Small controlled trials + animal models · Faster healing / less irritation
C
Hair growth / density
Weak human evidence
Mechanistic + small studies · Suggestive
D
Systemic / injectable "anti-aging / resets gene expression"
Bioinformatic/in vitro only; no human systemic-efficacy trials; "reverses aging" is not demonstrated
In-vitro / bioinformatic (Connectivity Map, ~4,000 genes toward a "younger" profile) · Broad gene modulation in vitro
F
"Rebuilds collagen" dermal synthesis
The human trials scored appearance endpoints — fine lines, firmness, the look of density — not dermal collagen; no biopsy or histology has measured collagen in skin after topical application. Synthesis of collagen and elastin was shown in fibroblast culture, and permeation through intact skin is near-zero.
Marketing claim
D
Safety (topical)
Topical generally well tolerated (occasional mild redness); systemic/injectable human safety not established
Widely used cosmetic; small trials · Well tolerated
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for GHK-Cu Peptide (Copper Tripeptide-1) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the appearance of firmer, smoother-looking skin
  • helps improve the look of fine lines
  • for a more even, radiant-looking complexion
  • antioxidant
✕ Not allowed (medicinal)
  • stimulates collagen synthesis
  • wound healing
  • heals
  • repairs skin
  • increases skin density/thickness
  • appearance of denser-looking skin
  • reverses aging
  • resets gene expression
  • treats…
  • hair growth
  • increases hair density

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a tripeptide (3 amino acids: glycine, L-histidine, L-lysine, < 40 aa → peptide) coordinated with a copper(II) ion. Occurs naturally in human plasma, saliva and urine; plasma levels decline ~60% between ages ~20 and ~60. First described by Loren Pickart (1973).

Development & history

  • Discovered by Loren Pickart in 1973: he identified a factor in human plasma that made aged liver tissue synthesise proteins like younger tissue — that factor was GHK, which binds copper as GHK-Cu (reported in Nature).
  • Over the following decades it was studied primarily for wound healing and tissue remodeling (including some clinical wound-care use), then migrated into cosmetics as Copper Tripeptide-1, commercialised first by Pickart's own company (Skin Biology) and later by many brands.
  • Today the topical form is a mainstream cosmetic ingredient; the injectable / systemic form remains a research compound with no approval anywhere in the world.

Mechanism (as proposed)

a copper-binding tripeptide that, in vitro, stimulates fibroblast collagen/elastin synthesis (Maquart 1988), modulates MMP/TIMP balance (orderly remodeling), acts as an antioxidant and anti-inflammatory (lowers IL-6/TNF-α), and is pro-angiogenic (VEGF); bioinformatic analyses report broad gene-expression modulation. Most of this is in vitro; in-vivo topical relevance is constrained by poor skin penetration.

Related reading

Scan your productSee if GHK-Cu Peptide (Copper Tripeptide-1) is in what you're usingOpen the scanner →
Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID73587
InChIKeyMVORZMQFXBLMHM-QWRGUYRKSA-N
SMILESC1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN
UNII39TG2H631E
DrugBankDB11296

via PubChem exact-name match (copper peptide) · high confidence

Sources — 8 cited
01Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide–copper complex GHK-Cu. FEBS Lett. 1988.
02Leyden JJ, et al. Clinical evaluation of a copper tripeptide cream and serum for photodamaged skin. J Cosmet Dermatol. 2002.
03Li (et al.). Skin permeation of GHK-Cu. Pharm Res. 2015. (near-zero permeation through intact skin.)
04Badenhorst T, et al. GHK-Cu nano-lipid carrier vs Matrixyl 3000, 8-week RCT. 2016.
05Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide (gene-expression review). Int J Mol Sci. 2018 (PMID 29986520).
06Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems, prospects. BioImpacts. 2024.
07FDA. Update to 503A Bulk Drug Substances Category 2 List — Removal of GHK-Cu and 10 other peptides. 15 April 2026 (Docket No. FDA-2025-N-6895).
08FDA. Pharmacy Compounding Advisory Committee — announced review of GHK-Cu (injectable and non-injectable routes) scheduled before end-February 2027.
Updated 2026-07-20 (US injectable status: interim — Category 2 removed 15 April 2026, PCAC review scheduled before end-February 2027; recheck after outcome)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
AHK-Cu (Copper Tripeptide-3)C
Peptide
Matrixyl (Palmitoyl Pentapeptide-4)B
Peptide
SNAP-8 (Acetyl Octapeptide-3)C
Peptide
Argireline (Acetyl Hexapeptide-8)C
Peptide
TB-500 (Thymosin Beta-4 fragment)C
Peptide
Vitamin C (L-Ascorbic Acid)A
Small molecule (non-peptide)
Explore by goal
Tissue repairSkin & aestheticHair & topical
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

RegionInternational
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen dataBrands
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.